A5032905819- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Cannabis and Cannabinoid Research
- Long-Term Effects of COVID-19
- Pancreatic function and diabetes
- Hemoglobinopathies and Related Disorders
- Hematopoietic Stem Cell Transplantation
- Cancer Immunotherapy and Biomarkers
- Autophagy in Disease and Therapy
- Epilepsy research and treatment
- Tryptophan and brain disorders
- Neuroscience and Neuropharmacology Research
- Prenatal Substance Exposure Effects
- Pharmacological Effects of Natural Compounds
- Sepsis Diagnosis and Treatment
- Immune Cell Function and Interaction
- Neuroblastoma Research and Treatments
- Genetic Neurodegenerative Diseases
- Genetics and Neurodevelopmental Disorders
- Biomedical Research and Pathophysiology
Hospital Universitario Quirónsalud Madrid
2022-2025
Universidad Europea
2023-2025
Hospital Quirónsalud Barcelona
2023
Instituto Ramón y Cajal de Investigación Sanitaria
2019-2020
Centro de Investigación Biomédica en Red
2020
Biomedical Research Networking Center on Neurodegenerative Diseases
2019-2020
Universidad Complutense de Madrid
2016
Abstract Cannabinoids have shown to exert neuroprotective actions in animal models by acting at different targets including canonical cannabinoid receptors and PPARγ. We previously showed that VCE-003, a cannabigerol (CBG) quinone derivative, is novel anti-inflammatory through now generated non-thiophilic VCE-003 derivative named VCE-003.2 preserves the ability activate PPARγ analyzed its activity. This compound exerted prosurvival action progenitor cells during neuronal differentiation,...
Abstract Prenatal exposure to Δ 9 -tetrahydrocannabinol (THC), the most prominent active constituent of cannabis, alters neurodevelopmental plasticity with a long-term functional impact on adult offspring. Specifically, THC affects development pyramidal neurons and GABAergic interneurons via cannabinoid CB 1 receptors (CB R). However, particular contribution these two neuronal lineages behavioral alterations deficits induced by is still unclear. Here, using conditional R knockout mice, we...
The administration of certain cannabinoids provides neuroprotection in models neurodegenerative diseases by acting through various cellular and molecular mechanisms. Many cannabinoid actions the nervous system are mediated CB1 receptors, which can elicit psychotropic effects, but other targets devoid activity, including CB2 nuclear PPARγ also be target specific cannabinoids. We investigated pro-neurogenic potential synthetic cannabigerol derivative, VCE-003.2, striatal neurodegeneration...
Our aim in this work is to find biomarkers optimize therapy with IL-6 inhibitors, as not all clinical trials have shown clear benefits on mortality or mechanical ventilation progression. Given the link between delayed seroconversion and higher complication risks, we test if evaluating SARS-CoV-2 spike protein antibody status before treatment could enhance inhibitor effectiveness COVID-19 patients. We conducted a post hoc analysis of COVACTA study, phase 3, randomized, double-blind,...
We aim to describe the safety and efficacy of sotrovimab in severe cases COVID-19 immunocompromised hosts.We used a retrospective multicenter cohort including hospitalized patients with treated between October 2021 December 2021.We included 32 patients. The main immunocompromising conditions were solid organ transplantation (46.9%) hematological malignancy (37.5%). Seven (21.9%) had respiratory progression: 12.5% died 9.4% required mechanical ventilation. Patients within first 14 days their...
The endocannabinoid (eCB) system, via the cannabinoid CB1 receptor, regulates neurodevelopment by controlling neural progenitor proliferation and neurogenesis. receptor signalling in vivo drives corticofugal deep layer projection neuron development through regulation of BCL11B SATB2 transcription factors. Here, we investigated role eCB mouse pluripotent embryonic stem cell-derived neuronal differentiation. Characterization system revealed increased expression eCB-metabolizing enzymes,...
Alterations of the PI3K/Akt/mammalian target rapamycin complex 1 (mTORC1) signalling pathway are causally involved in a subset malformations cortical development (MCDs) ranging from focal dysplasia (FCD) to hemimegalencephaly and megalencephaly. These MCDs represent frequent cause refractory paediatric epilepsy. The endocannabinoid system -especially cannabinoid CB1 receptor- exerts neurodevelopmental regulatory role at least part via activation mTORC1 signalling. Therefore, we sought...
To study the effect of plitidepsin antiviral treatment in immunocompromised COVID-19 patients with underlying haematological malignancies or solid tumours, particularly those who have undergone anti-CD20 therapies.
To evaluate the compassionate use of plitidepsin as an antiviral treatment in hospitalized immunocompromised adult patients with moderate-to-severe COVID-19.Retrospective observational study data -collected from January 01, 2021 to April 30, 2022- 35 COVID-19 non-eligible for other available treatments. Main outcome measures were time respiratory recovery (SpFi ≥ 315); COVID-19-related 30-day-cumulative mortality after first infusion; and undetectable levels viral RNA.Thirty-three receiving...
Use of interleukin (IL-6) inhibitors has become one the most complicated clinical issues in treating coronavirus disease 2019 (COVID-19). Recently, randomized open-label platform trials have found that IL-6 a beneficial effect on mortality severe COVID-19. However, several questions arise around their mechanism action this disease, as well how, when, and at which dose they should be used. both proinflammatory anti-inflammatory effects, may modulate course COVID-19, whose immunopathogenesis...
Background: Immunocompromised patients are more vulnerable to SARS-CoV-2 infection and develop respiratory insufficiency. In a phase I clinical trial, treatment with plitidepsin, resulted in viral load reductions improvement on inflammatory biomarkers. Previously published case reports of immunocompromised COVID-19 treated plitidepsin reinforce the safety drug.Methods: This study aimed evaluate compassionate use as an antiviral hospitalized adult moderate-to-severe COVID-19. The primary...